Although the findings from Villeda et al. 4 that a factor or factors present in a young systemic circulation is able to reverse certain aspects of brain aging are exciting, they are not without precedent. These authors have previously reported that the circulating chemokine CCL11 promotes neurogenesis (the formation of new neurons) in brain 7 . Moreover, several recent publications using heterochronic parabiosis lend support to this general observation. For example, Ruckh et al. 8 reported that recovery from experimentally induced brain demyelination is enhanced in aged mice exposed to a young systemic environment. Salpeter et al. 9 showed that the age-related decline in pancreatic β-cell proliferation can be reversed in aged-young parabionts. Finally, Loffredo et al. 10 , using a similar approach, identified the transforming growth factor-β superfamily member GDF11 as a circulating factor in young mice that reduces age-related cardiac hypertrophy and even heart failure in aged mice. In two very recent publications this work was extended to show that systemic administration of GDF11 to aged mice can partially reverse age-related skeletal muscle dysfunction, increase cerebrovascular proliferation and promote neurogenesis in the subventricular zone 11, 12 . Taken together, it appears there may be multiple brain-rejuvenating factors (and mechanisms) yet to be identified.
Villeda et al. 4 provide compelling evidence for a circulating factor or factors in young mice that can rejuvenate synaptic and cognitive deficits in aged mice. However, as with many such studies, we are left with many more questions than answers. What is the aged mice exposed to young blood were also associated with enhanced long-term potentiation (LTP), a long-lasting strengthening of the response of postsynaptic neurons to repeated presynaptic stimulation that represents a well-accepted cellular model of learning and memory (Fig. 1) .
As noted above, the increase in synaptic plasticity associated with heterochronic parabiosis could potentially improve the impaired memory and learning behavior of aged mice. To test this more directly, the authors carried out systemic treatment of aged (18-month-old) mice with 'young' plasma from 3-month-old mice over 21 d and tested them using the radial arm maze, a test of spatial learning and memory, and a contextual fear conditioning memory task. They found that treatment of aged mice with young plasma improved memory performance to levels comparable to those of young mice. Moreover, heat denaturation of young plasma completely eliminated its beneficial effects in the contextual fear conditioning memory task. Given the heat lability of this factor or factors and the fact that the young plasma used in these experiments was extensively dialyzed to remove heparin, the rejuvenating factor(s) is probably a protein or large polypeptide (or a small molecule attached to a protein). Finally, in an elegant set of parabiosis experiments, the authors went on to show by inducing expression of a dominant-negative inhibitory form of Creb that Creb signaling within the hippocampus of aged mice appears to partially mediate the effects of young blood on synaptic plasticity and cognitive performance in aged mice.
rejuvenating factor, or, more likely, factors, present in young blood? Where is it produced, how is it regulated and how exactly does it work? Are its synaptotrophic effects limited to only one small region of the brain? How conserved might these factors be across species? It is also possible that there are systemic inhibitory factors in aged mice, and, in fact, there may well be a delicate balance of beneficial and deleterious synaptotrophic factors that occurs during aging. Furthermore, regarding the development of therapies, could the plasma from young human donors rejuvenate the brains of aged human recipients? Potentially, upon identification of the rejuvenating factor or factors, this could be exploited to develop new drugs to treat cognitive decline in healthy aging or in diseases of pathologic aging such as Alzheimer's disease. Most exciting is the distinct possibility that many deleterious consequences of brain aging may be reversible and effectively treated with an entirely new class of medicines.
unidentified envelope neutralization targets may still exist, and multiple neutralizing antibody specificities that are not yet known may also be involved. Identifying HIV-infected patients and cohorts with substantial neutralization breadth and potentially new neutralization targets is important in defining new immunogen designs for vaccine-mediated induction of bNAbs. Recent studies have demonstrated the interplay between virus evolution and antibody maturation leading to the HIV-1 bNAbs are generated in the HIV-1-positive population in a continuum of potency and breadth. In general, these responses appear late, usually between the second and fourth years after infection. Work in infected adults has helped to define the pathway that orchestrates induction of bNAbs in individuals where both the virus and B cell responses can be studied from the time of transmission to the presence of bNAbs 1,2 . These studies have been done only in adults, and although they have uncovered conserved targets on the HIV-1 envelope for neutralization breadth, 
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Infant Ab neutralization breadth development of bNAbs 1, 3 and have provided new insights on how B cell-lineage vaccine strategies might be able to mimic these pathways toward the maturation of bNAbs 4 .
Although neutralization breadth has been extensively characterized in HIV-1-infected adults, it has been unknown whether infants, who usually have higher viral loads and can progress to AIDS quickly, can also develop bNAbs. In this issue of Nature Medicine, Goo et al. 5 show that a subset of the HIV-1-infected infants studied developed varying levels of bNAbs within the first 24 months of infection (Fig. 1) . As bNAbs can develop early in life, the findings demonstrate that the neonatal naive B cell and T helper repertoires are equipped to respond to HIV-1 envelope in a manner that can induce broadly reactive anti-HIV neutralizing antibodies.
The authors measured the neutralization breadth of antibodies in plasma samples collected at least after 12 months of birth from 28 HIV-1-infected infants from the Nairobi Breastfeeding Trial who were infected with clade A, C or D viruses either in utero, during delivery or via breastfeeding 5 . Maternally derived antibodies waned within the first 3 months of infection and predominantly targeted easy-to-neutralize viruses. Subsequent development of de novo cross-clade responses arose in some the infants by ~1 year after infection, with continued development of neutralization breadth in some infants by 20 months after transmission. Envelopespecific binding responses and viral load set point correlated with broad neutralization, consistent with a previous report in adults 4 and suggesting that the high viral load found in HIV-infected infants may contribute to bNAb maturation.
Although only a small fraction of HIV-1-infected adults have broad and potent neutralization breadth, the overall neutralizing antibody response is a continuum, with many more infected individuals having some level of bNAbs than previously thought 6 . Single epitope specificities can be attributed to neutralization breadth in some individuals; however, other studies suggest the involvement of multiple specificities [7] [8] [9] [10] . Goo et al. 5 tested the known neutralization targets, the CD4 binding site, glycan-dependent V1-V2, glycan-dependent V3 and the membrane-proximal external region, using both experimental mapping and computational approaches 11 for defining neutralizing epitope specificities. However, no known bNAb epitope specificity could be ascribed to the infant plasma neutralization breadth, indicating that either a new neutralization target was involved or that multiple antibody specificities were contributing to the neutralization breadth. Indeed, recent studies have identified additional epitope targets for bNAbs involving the gp120 and gp41 regions in the native envelope spike [12] [13] [14] that could be considered for measurement in follow-up studies to epitope map neutralization breadth in HIV-1-infected infants.
One path toward an efficacious HIV-1 vaccine strategy is the induction of antibodies that can neutralize a diverse range of circulating viruses in a population. In adults, the development of neutralizing antibodies has been reported to take 2-4 years after virus transmission 15 , and these antibodies are associated with unique characteristics such as high levels of somatic mutation 16 , long complementarity-determining region H3 (CDRH3) and polyreactivity and/or autoreactivity, among others 17 . The high level of somatic mutation and rare CDRH3 length is a formidable challenge for developing an HIV-1 vaccine based on bNAbs, as the goal is to generate bNAbs as soon as possible after vaccination and with the minimum number of immunizations possible. The findings in infants, taken together with others from studies in adults 1, 18 , suggest that in some individuals, development of bNAbs can arise within the first 2 years, suggesting that there might be shorter pathways toward the development of bNAbs. The study by Goo et al. 5 highlights how tracking the existence and development of neutralizing antibodies in infants could provide insights into what hopefully will turn out to be new bNAb targets, thus potentially increasing the repertoire of potential bNAbs for vaccine development.
The time of development of bNAbs in infants 5 is coincident with some studies on the earliest time of bNAb development reported for adults 1, 18 . Whether induction of neutralization breadth is more commonly elicited earlier in infants than in adults was not rigorously addressed in this study, but the study by Goo et al. 5 does raise this possibility. Additional side-by-side studies with larger numbers of patients would be needed to directly address how different the timing of neutralization breadth and potency is between adults and infants. However, this will be difficult to do because of the decline in perinatal HIV-1 transmission as a result of implementation of numerous prevention strategies and improved treatment interventions for infected infants.
Nonetheless, the demonstration by Goo et al. 5 that infants can make bNAbs leads to a proof of concept for immunization of infants in that these responses can be generated early in life. Determining whether there is a benefit for infant vaccination over vaccination npg details are available in the online version of the paper (doi:10.1038/nm.3598).
